2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4882
    (Pyr3)-Amyloid β-Protein (3-42)
    (Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits.
    (Pyr3)-Amyloid β-Protein (3-42)
  • HY-N0651R
    Spinosin (Standard)
    		Inhibitor
    Spinosin (Standard) is the analytical standard of Spinosin. This product is intended for research and analytical applications. Spinosyn is a kind of effective C-saccharide, which has a protective effect. Spinosyn is active through Nrf2/HO-1 pathway inhibition Aβ1-42's production and combination.
    Spinosin (Standard)
  • HY-146151
    γ-Secretase modulator 12
    		Inhibitor
    γ-Secretase modulator 12 (Compound 1a) is a γ-secretase modulator that can selectively decrease amyloid-β42 (Aβ42) levels (IC50 of 0.39 µM). γ-Secretase modulator 12 can be used for Alzheimer’s disease research. γ-Secretase modulator 12 has a good brain/plasma ratio (Kp, brain = 0.72) in mice.
    γ-Secretase modulator 12
  • HY-W176465
    BTA-2
    BTA-2, a benzothiazole dye, is structurally similar to thioflavin T (ThT), which exhibits an enhanced fluorescence signal when bound to amyloid fibrils. BTA-2 has distinct absorption and emission characteristics in solution and when bound to amyloid fibrils, which makes it can used for identifying amyloid fibrils using spectroscopy.
    BTA-2
  • HY-P2283
    β-Amyloid (1-37) (human)
    β-Amyloid (1-37) (human) correlates moderately with Mini-Mental State Examination (MMSE) scores in Alzheimer disease. β-Amyloid (1-37) (human) possesses an added diagnostic value.
    β-Amyloid (1-37) (human)
  • HY-P4788
    Acetyl-Amyloid β-Protein (1-6) amide
    		Chemical
    Acetyl-Amyloid β-Protein (1-6) amide is a hexapeptide that contains a potential copper(II) binding site. Acetyl-Amyloid β-Protein (1-6) amide can be used for research of Alzheimer's disease and related disorders.
    Acetyl-Amyloid β-Protein (1-6) amide
  • HY-W004287S
    Methyl tridecanoate-d25
    		Inhibitor
    Methyl tridecanoate-d25 is the deuterium labeled Methyl tridecanoate. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE)[1].
    Methyl tridecanoate-d<sub>25</sub>
  • HY-P10628
    β Amyloid (1-14), human
    β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research.
    β Amyloid (1-14), human
  • HY-P991073
    MEDI-1814
    		Inhibitor
    MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    MEDI-1814
  • HY-P4740
    β-Amyloid (35-25)
    β-Amyloid (35-25) is areverse version of β-Amyloid (25-35) (HY-P0128).
    β-Amyloid (35-25)
  • HY-P4887
    Amyloid β-Protein (1-6)
    Amyloid β-Protein (1-6) is aAβ Fragment.
    Amyloid β-Protein (1-6)
  • HY-N0931R
    Santacruzamate A (Standard)
    		Inhibitor
    Santacruzamate A (Standard) is the analytical standard of Santacruzamate A. This product is intended for research and analytical applications. Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research[1][2].
    Santacruzamate A (Standard)
  • HY-144326
    Aβ-IN-1
    		Inhibitor
    Aβ-IN-1 is a Aβ1-42 aggregation inhibitor. Aβ-IN-1 inhibits Aβ1-42 self-aggregation in vitro by delaying the exponential growth phase or reduces the quantity of fibrils in the steady state. Aβ-IN-1 can be used for the research of conformational disorders.
    Aβ-IN-1
  • HY-P3846
    (Glu20)-Amyloid β-Protein (1-42)
    (Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease.
    (Glu20)-Amyloid β-Protein (1-42)
  • HY-168859
    JNK3 inhibitor-9
    JNK3 inhibitor-9 (Compound 24a) is a potent, selective and BBB-permeable JNK3 inhibitor with an IC50 value of 12 nM. JNK3 inhibitor-9 also potently inhibits GSK3α/β (IC50s: 14 and 35 nM, respectively) involved in Tau phosphorylation. JNK3 inhibitor-9 reduces c-Jun and APP phosphorylation. JNK3 inhibitor-9 protects neurons from Aβ1-42 toxicity.
    JNK3 inhibitor-9
  • HY-163382
    Cbz-Gly-Pro-Ala-O-cinnamyl
    		Inhibitor
    Cbz-Gly-Pro-Ala-O-cinnamyl (compound 25) is a small peptide targeting BACE-1 and AChE with the IC50 values of 0.02 μM and 1 μM, respectively. Cbz-Gly-Pro-Ala-O-cinnamyl shows neuroprotective effect and can be used for study of Alzheimer’s disease.
    Cbz-Gly-Pro-Ala-O-cinnamyl
  • HY-P0128A
    β-Amyloid (25-35), HFIP-treated
    β-Amyloid (25-35) (Amyloid beta-peptide (25-35)), HFIP-treated is a β-Amyloid (25-35) (HY-P0128) treated with HFIP. β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.
    β-Amyloid (25-35), HFIP-treated
  • HY-149273
    hBChE-IN-1
    		Inhibitor
    hBChE-IN-1 (compound 4), a quinolizidinyl derivative, is a potent hBChE inhibitor (IC50=7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against tau and Aβ40 protein aggregation, with IC50 values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research.
    hBChE-IN-1
  • HY-157441
    AChE/Aβ-IN-4
    		Inhibitor
    AChE/Aβ-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and β-amyloid (Aβ) aggregation, with the IC50 values of 1.72 ± 0.18 μM and 1.42 ± 0.3 μM, respectively. AChE/Aβ-IN-4 plays an impotant role in neurological disorders, such as Alzheimer’s disease.
    AChE/Aβ-IN-4
  • HY-P4926
    Mca-SEVKMDAEFRK(Dnp)RR-NH2
    Mca-SEVKMDAEFRK(Dnp)RR-NH2, containing the wild-type amyloid precursor protein (APP) beta-secretase cleavage site, is the substrate of thimet oligopeptidase (TOP). It is used for Alzheimer's disease research.
    Mca-SEVKMDAEFRK(Dnp)RR-NH2
Cat. No. Product Name / Synonyms Application Reactivity